Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.
—
Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.
—
Daily adjusted close
Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.